Page last updated: 2024-12-05

androsterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5879
CHEMBL ID87285
CHEBI ID16032
SCHEMBL ID269981
MeSH IDM0001116

Synonyms (117)

Synonym
AC-16145
CHEMBL87285 ,
caswell no. 051g
brn 2217626
5-alpha-androstan-17-one, 3-alpha-hydroxy-
nsc 9898
einecs 200-173-4
epa pesticide chemical code 126501
MLS001146886
MLS002153256
cis-androsterone
5alpha-androsterone
CHEBI:16032 ,
(3alpha,5alpha)-3-hydroxyandrostan-17-one
5alpha-androstane-3alpha-ol-17-one
3alpha-hydroxyetioallocholan-17-one
androstan-17-one, 3-hydroxy-, (3.alpha.,5.alpha.)-
smr000058571
MLS000069394 ,
PRESTWICK2_000411
androkinine
nsc9898
u 6036
3.alpha.-hydroxyetioallocholan-17-one
3-epihydroxyetioallocholan-17-one
atromide ici
5.alpha.-androstan-17-one, 3.alpha.-hydroxy-
androtine
nsc-9898
3.alpha.-hydroxy-17-androstanone
5.alpha.-androstane-3.alpha.-ol-17-one
5.alpha.-androsterone
PRESTWICK_689
cas-53-41-8
BSPBIO_000362
LMST02020001
BPBIO1_000400
PRESTWICK3_000411
3alpha-hydroxy-17-androstanone
5alpha-androstan-17-one, 3alpha-hydroxy-
androstan-17-one, 3-hydroxy-, (3alpha,5alpha)-
3-alpha-hydroxy-5-alpha-androstan-17-one
5-alpha-androstan-3-alpha-ol-17-one
3-alpha-hydroxyetioallocholan-17-one
androstanon-3-alpha-ol-17-one
3-alpha-hydroxy-17-androstanone
androstan-17-one, 3-hydroxy-, (3-alpha,5-alpha)-
AOI ,
UPCMLD-DP124:001
3alpha-hydroxy-5alpha-androstan-17-one
53-41-8
androsterone ,
C00523
UPCMLD-DP124
1X8J
NCGC00161664-01
SPBIO_002301
PRESTWICK1_000411
PRESTWICK0_000411
NCGC00161664-02
5alpha-androstan-3alpha-ol-17-one
086DA2D0-D9AE-4593-9E08-991AF2BF2A47
androstan-17-one, 3alpha-hydroxy-, 5alpha-
BMSE000543
MLS000563085
3-hydroxyandrostan-17-one
HMS1569C04
(3r,5s,8r,9s,10s,13s,14s)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
HMS2096C04
A0646
HMS2230I18
4-08-00-00642 (beilstein handbook reference)
c24w7j5d5r ,
unii-c24w7j5d5r
esterase basic kit
androkinin
androsterone [mi]
3.alpha.-hydroxy-5.alpha.-androstan-17-one
(3.alpha.,5.alpha.)-3-hydroxyandrostan-17-one
EPITOPE ID:174330
AKOS015894886
S6352
CCG-220411
SCHEMBL269981
bdbm17639
(1s,2s,5r,7s,10r,11s,15s)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadecan-14-one
3alpha-hydroxy-5alpha-androstane-17-one
dtxsid3036525 ,
tox21_303701
dtxcid1016525
NCGC00357021-01
androstan-17-one, 3-hydroxy-, (3a,5a)-
OPERA_ID_584
sr-01000759187
SR-01000759187-3
GS-3614
(1s,2s,5r,7s,10r,11s,15s)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-one
(1s,2s,5r,7s,10r,11s,15s)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0?,?.0??,??]heptadecan-14-one
androsterone, vetranal(tm), analytical standard
HMS3713C04
5-alpha-androsterone
3-alpha-hydroxy-5alpha-androstan-17-one
5-alpha-androstane-3alpha-ol-17-one
3-alpha-hydroxy-5-alpha-androstane-17-one
3-hydroxy-(3-alpha,5-alpha)-androstan-17-one
(3alpha,5beta,8alpha,10alpha,13alpha,14beta)-3-hydroxyandrostan-17-one
'(3alpha,5beta,8alpha,10alpha,13alpha,14beta)-3-hydroxyandrostan-17-one'
Q422469
HY-N0933
CS-0014230
D95612
(3r,5s,8r,10s,13s)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one
5-androstan-3-ol-17-one
5a-androstan-3a-ol-17-one
A923412
(3r,5s,8r,9s,10s,13s,14s)-3-hydroxy-10,13-dimethylhexadecahydro-17h-cyclopenta[a]phenanthren-17-one
androsterolone

Research Excerpts

Overview

Epiandrosterone (EA) is an uncompetitive inhibitor of trypanosomal G6PDH for which its binding site to the enzyme remains unknown. EA appears to be a useful tool to explore the mechanism by which G6 PD deficiency enhances susceptibility to hemolytic drugs.

ExcerptReferenceRelevance
"Androsterone is a male sex steroid hormone, being the first steroid hormone from this category isolated and discovered 90 years ago."( Steroid Hormone Androsterone Observed in the Gas Phase by Rotational Spectroscopy.
Caliebe, SVM; Pinacho, P; Schnell, M, 2022
)
1.79
"Epiandrosterone (EA) is an uncompetitive inhibitor of trypanosomal G6PDH for which its binding site to the enzyme remains unknown."( Binding Mode and Selectivity of Steroids towards Glucose-6-phosphate Dehydrogenase from the Pathogen Trypanosoma cruzi.
Botta, M; Comini, MA; Hamilton, N; Medeiros, A; Moraca, F; Ortiz, C, 2016
)
0.95
"Epiandrosterone appears to be a useful tool to explore the mechanism by which G6PD deficiency enhances susceptibility to hemolytic drugs."( Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.
Budinsky, R; Grossman, S; Jollow, D, 1995
)
0.81

Actions

ExcerptReferenceRelevance
"Epiandrosterone was found to inhibit rat red cell G6PD uncompetitively and to suppress red cell hexose monophosphate shunt activity by more than 95%."( Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.
Budinsky, R; Grossman, S; Jollow, D, 1995
)
0.81

Toxicity

ExcerptReferenceRelevance
" Although the toxic effects of paraquat are associated with the generation of very active superoxides, U2 cells contained higher levels of superoxide dismutase and catalase than RLF cells."( Protection of a rat tracheal epithelial cell line from paraquat toxicity by inhibition of glucose-6-phosphate dehydrogenase.
Ho, IC; Kao, SL; Lai, GJ; Lee, TC; Wu, CW, 1993
)
0.29
"There were no differences in the clinical laboratory values or in reported minor adverse experiences, between treatment and placebo groups."( Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
Davidson, M; Lardy, H; Maki, K; Marwah, A; Marwah, P; Sawchuk, RJ; Weeks, C, 2000
)
0.53
"These results indicate that 3beta-acetyl-7-oxo-DHEA is safe and well tolerated in normal healthy men at doses up to 200 mg/d for 4 weeks."( Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
Davidson, M; Lardy, H; Maki, K; Marwah, A; Marwah, P; Sawchuk, RJ; Weeks, C, 2000
)
0.53
" The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42."( Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients.
Destiche, DA; Frincke, JM; Garsd, A; Noveljic, Z; Stickney, DR, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" Antiepileptic drugs, particularly classical ones, substantially modify bioavailability of androgens and can inhibit the activity of hypothalamo-pituitary-testicular axis, and--in a consequence--aggravate hypogonadism."( [Androgens and epilepsy].
Mróz, K; Mróz, T; Tutka, P, 2010
)
0.36

Dosage Studied

16beta-hydroxyandrosterone sulphate was found to be readily absorbed with 50 to 75% recovery of dosing after 24 h, and with glucuro- and sulfoconjugates of DHEA, androsterone, and etiocholanolone as most abundant metabolites.

ExcerptRelevanceReference
" The classification of the anti-androgens, their indications, side-effects, dosage schemes and results of treatment are reviewed."( [Clinical aspects of the anti-androgens].
Holtzhausen, GH, 1979
)
0.26
"The chemical synthesis of 16beta-hydroxyandrosterone was described preparatory to studies of the disulphates of the 16-oxygenated ketonic C19 steroids present in the bile of female rats dosed with [3H]androsterone sulphate."( Disulphates of 16-oxygenated ketonic C19 steroids as biliary metabolities of androsterone sulphate in female rats.
Hakozaki, M; Matsui, M, 1978
)
0.75
" The dose-response and time course of response for the three steriods were nearly identical."( Serum 5alpha-androstane-3alpha,17beta-diol, androsterone, and testosterone concentrations in the male rat. Influence of age and gonadotropin stimulation.
Moger, WH, 1977
)
0.52
" Further, there is a dose-response relationship but no apparent synergism between exogenous dihydrotestosterone and incubation temperature."( Temperature and non-aromatizable androgens: a common pathway in male sex determination in a turtle with temperature-dependent sex determination?
Bergeron, JM; Cantú, AR; Crews, D, 1996
)
0.29
" While testosterone treatment at physiological doses resulted in stimulation of GtH-II-alpha and -beta subunit mRNA production, time-course and dose-response studies performed on sexually immature goldfish of mixed sex, using a wider dose range exceeding physiological levels, demonstrated a biphasic response to in vivo androgen treatment."( Effect of testosterone on maturational gonadotropin subunit messenger ribonucleic acid levels in the goldfish pituitary.
Habibi, HR; Huggard, D; Kassam, G; Khakoo, Z; Mahmoud, SS, 1996
)
0.29
" Quantitative analysis by gas chromatography-mass spectrometry with selected ion monitoring demonstrated that the drug was readily absorbed with 50 to 75% recovery of dosing after 24 h, and with glucuro- and sulfoconjugates of DHEA, androsterone, and etiocholanolone as the most abundant metabolites."( Oral administration of dehydroepiandrosterone to healthy men: alteration of the urinary androgen profile and consequences for the detection of abuse in sport by gas chromatography-mass spectrometry.
Dehennin, L; Ferry, M; Lafarge, JP; Lafarge, P; Pérès, G, 1998
)
0.76
" In Experiment 4, a high dosage of 5alpha-dihydrotestosterone was more anxiolytic than a high dosage of estradiol benzoate, suggesting that testosterone action may require 5alpha-reduction."( Testosterone rapidly reduces anxiety in male house mice (Mus musculus).
Aikey, JL; Anmuth, DM; James, PJ; Nyby, JG, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
androgenA sex hormone that stimulates or controls the development and maintenance of masculine characteristics in vertebrates by binding to androgen receptors.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
anticonvulsantA drug used to prevent seizures or reduce their severity.
pheromoneA semiochemical used in olfactory communication between organisms of the same species eliciting a change in sexual or social behaviour.
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
3alpha-hydroxy steroidA 3-hydroxy steroid in which the 3-hydroxy substituent is in the alpha-position.
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
androstanoidAny steroid based on an androstane skeleton and its derivatives.
C19-steroidA steroid compound with a structure based on a 19-carbon (androstane) skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Androstenedione Metabolism1823
Male steroid hormones in cardiomyocyte energy metabolism1119
testosterone and androsterone degradation to androstendione36
superpathway of testosterone and androsterone degradation1136
Biochemical pathways: part I0466
Alternative pathway of fetal androgen synthesis717

Protein Targets (40)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency39.91490.002541.796015,848.9004AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency28.39520.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
GLI family zinc finger 3Homo sapiens (human)Potency19.33120.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency41.53600.000221.22318,912.5098AID1259243; AID1259381
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency36.44710.000657.913322,387.1992AID1259377; AID1259378
progesterone receptorHomo sapiens (human)Potency19.33120.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency43.27710.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency34.66540.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency62.12530.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency59.00240.000229.305416,493.5996AID1259244; AID1259248
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency48.96620.057821.109761.2679AID1159528
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency8.91250.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency54.48270.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency54.48270.001551.739315,848.9004AID1259244
TAR DNA-binding protein 43Homo sapiens (human)Potency17.78281.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, retinol dehydrataseSpodoptera frugiperda (fall armyworm)Ki0.11000.11000.11000.1100AID977610
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Corticosteroid-binding globulinHomo sapiens (human)Ki2.45470.01323.248110.0000AID51055
Glucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)IC50 (µMol)200.00005.18007.32009.4000AID672987
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)40.73800.00101.979414.1600AID255211
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.505710.0000AID71982
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.497310.0000AID71982
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.498810.0000AID71982
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.504610.0000AID71982
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Solute carrier organic anion transporter family member 1A1Rattus norvegicus (Norway rat)Ki10.60001.10004.51259.8000AID681147
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.506510.0000AID71982
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.505710.0000AID71982
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)1.36700.00010.507510.0000AID71982
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sex hormone-binding globulinHomo sapiens (human)Kd0.07080.00020.34964.7863AID318680
G-protein coupled bile acid receptor 1Homo sapiens (human)EC50 (µMol)6.22000.02372.52598.9000AID324923
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (49)

Processvia Protein(s)Taxonomy
glucocorticoid metabolic processCorticosteroid-binding globulinHomo sapiens (human)
negative regulation of endopeptidase activityCorticosteroid-binding globulinHomo sapiens (human)
pentose-phosphate shuntGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
lipid metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cholesterol biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADPH regenerationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glutathione metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose-phosphate shunt, oxidative branchGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to iron(III) ionGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein glutathionylationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to organic cyclic compoundGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
pentose biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
substantia nigra developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to foodGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cellular response to oxidative stressGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
erythrocyte maturationGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
regulation of neuron apoptotic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
response to ethanolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
ribose phosphate biosynthetic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose 6-phosphate metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of reactive oxygen species metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose metabolic processGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
androgen bindingSex hormone-binding globulinHomo sapiens (human)
protein bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingSex hormone-binding globulinHomo sapiens (human)
steroid bindingCorticosteroid-binding globulinHomo sapiens (human)
serine-type endopeptidase inhibitor activityCorticosteroid-binding globulinHomo sapiens (human)
glucose-6-phosphate dehydrogenase activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
glucose bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
identical protein bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
protein homodimerization activityGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
NADP bindingGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
extracellular regionSex hormone-binding globulinHomo sapiens (human)
extracellular exosomeSex hormone-binding globulinHomo sapiens (human)
extracellular regionCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
extracellular exosomeCorticosteroid-binding globulinHomo sapiens (human)
extracellular spaceCorticosteroid-binding globulinHomo sapiens (human)
cytoplasmGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytoplasmic side of plasma membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
membraneGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
centriolar satelliteGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
intracellular membrane-bounded organelleGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
extracellular exosomeGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
cytosolGlucose-6-phosphate 1-dehydrogenaseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID51055Binding affinity to human CBG receptor (corticosteroid-binding globulins)2004Journal of medicinal chemistry, May-20, Volume: 47, Issue:11
Comparative molecular active site analysis (CoMASA). 1. An approach to rapid evaluation of 3D QSAR.
AID624621Specific activity of expressed human recombinant UGT2B7Y2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID221372Hypnotic dose required to cause a loss of righting reflex for a minimum period of 30 s in 50 percent of treated mice after intravenous administration.2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Conformationally constrained anesthetic steroids that modulate GABA(A) receptors.
AID382397Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis expressed in assessed as ratio of current in treated to non-treated oocyte at 1 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID127351Binding affinity against human monoclonal antibody (mAb)-5C22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID266559Loss of righting reflex in Xenopus laevis tadpole2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID266557Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID382399Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis assessed as ratio of current in drug-treated to GABA-treated oocyte at 10 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID468985Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID321357Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus lavies oocytes assessed as ratio of effect on current at 10 uM drug to absence of compound by electrophysiology method2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID659061Modulation of rat alpha1beta2gamma2L GABAA receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride currents at 0.1 uM by electrophysiology assay relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID127350Binding affinity against human monoclonal antibody (mAb)-1B32002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID659068Anesthetic effect on Xenopus laevis tadpole assessed as loss of righting reflex2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID188186Effect on the potentiation of muscimol-stimulated 36Cl- uptake in rat brain synaptoneurosomes1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis, metabolism, and pharmacological activity of 3 alpha-hydroxy steroids which potentiate GABA-receptor-mediated chloride ion uptake in rat cerebral cortical synaptoneurosomes.
AID382391Displacement of [35S]TPBS from GABAA receptor in rat brain2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID51062In silico steroid binding affinity to transport protein corticosteroid binding globulin1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID468984Inhibition of human 17beta-HSD7 expressed in HEK293 cells assessed as inhibition of reduction of [14C]estrone into [14C]estradiol at 0.3 uM after 7 hrs2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
AID659064Modulation of rat alpha1beta2gamma2L GABAA receptor expressed in Xenopus laevis oocytes assessed as potentiation of chloride currents at 10 uM by electrophysiology assay relative to GABA2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID659062Modulation of rat alpha1beta2gamma2L GABAA receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride currents at 1 uM by electrophysiology assay relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID321359Anesthetic effect on Xenopus lavies tadpole assessed as loss of righting reflex2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID321355Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus lavies oocytes assessed as ratio of effect on current at 0.1 uM drug to absence of compound by electrophysiology method2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID382395Anesthetic effect in Xenopus laevis assessed as loss of swimming response at 10 uM2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID321361Anesthetic effect on Xenopus lavies tadpole assessed as loss of swimming reflex at 10 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID672987Inhibition of human recombinant N-terminal His tagged G6PD expressed in Escherichia coli JM109 (DE3) cells assessed as production of NADPH after 30 mins by Amplite fluorimetric assay2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID382398Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis expressed in assessed as ratio of current in treated to non-treated oocyte at 10 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID266562Loss of swimming reflex in Xenopus laevis tadpole at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID318680Displacement of [3H]5alpha dihydrotestosterone from human sex hormone binding globulin2008Journal of medicinal chemistry, Apr-10, Volume: 51, Issue:7
An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID71982Inhibition of binding of tert-butyl bicyclophosphorothionate ([35 S]TBPS) at Gamma-aminobutyric acid A receptor from rat whole brain membranes2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Conformationally constrained anesthetic steroids that modulate GABA(A) receptors.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1337728Inhibition of recombinant human CYP1B1 expressed in bacterial microsomes co-expressing P450 reductase at 3 uM using 7-ethyl-O-resorufin as substrate after 45 mins in presence of NADPH by fluorescence assay relative to control2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting cytochrome P450 (CYP) 1B1 with steroid derivatives.
AID212919Binding affinity towards testosterone binding globulin is expressed as log(1/k).1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID50906Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity2003Journal of medicinal chemistry, Oct-23, Volume: 46, Issue:22
Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor.
AID266558Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of GABA at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID1653689Inhibition of 3-alpha-diol conversion to 5-alpha-dihydrotestosterone in human LAPC4 cells assessed in 200000 cells at 10 uM measured after 24 hrs using [14C]-3-alpha-diol/[14C]-3-beta-diol (9:1) as non-radiolabeled/radiolabeled 20:1 mixture by TLC analysi2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells - Identifying inhibitors of non-classical pathways producing the most potent androgen.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID659059Displacement of [35S]TBPS from GABAA receptor picrotoxin binding site in rat brain membranes2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID659070Anesthetic effect on Xenopus laevis tadpole assessed as loss of swimming reflex at 10 uM2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID624620Specific activity of expressed human recombinant UGT2B7H2000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID321354Displacement of [35S]TBPS from GABAA receptor in rat brain membrane2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID51049Binding affinity against corticosteroid-binding globulin1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID51058Binding affinity towards corticosteroid-binding globulin (CBG)2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID127349Binding affinity against human monoclonal antibody (mAb)-11E62002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID324923Agonist activity at human TGR5 expressed in CHO cells by luciferase assay2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID127352Binding affinity against human monoclonal antibody (mAb)-7F22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Three-dimensional quantitative structure-activity relationship analysis of ligand binding to human sequence antidigoxin monoclonal antibodies using comparative molecular field analysis.
AID1653690Inhibition of 3-alpha-diol conversion to 5-alpha-dihydrotestosterone in human LAPC4 cells assessed in 200000 cells at 3 uM measured after 24 hrs using [14C]-3-alpha-diol/[14C]-3-beta-diol (9:1) as non-radiolabeled/radiolabeled 20:1 mixture by TLC analysis2020Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
Formation of 5α-dihydrotestosterone from 5α-androstane-3α,17β-diol in prostate cancer LAPC-4 cells - Identifying inhibitors of non-classical pathways producing the most potent androgen.
AID51054Binding affinity for corticosteroid binding globulin is expressed as log(1/k)1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID255211Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881)2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Impact of induced fit on ligand binding to the androgen receptor: a multidimensional QSAR study to predict endocrine-disrupting effects of environmental chemicals.
AID212920Binding affinity against transport protein testosterone binding globulin.1994Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15
Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID681147TP_TRANSPORTER: inhibition of E217betaG uptake in Oatp1-expressing HeLa cells1996The American journal of physiology, Feb, Volume: 270, Issue:2 Pt 2
Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter.
AID321358Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis oocytes assessed as gating effect at 10 uM by electrophysiology method2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID51059Binding affinity to corticosteroid binding globulin1998Journal of medicinal chemistry, Jul-02, Volume: 41, Issue:14
Three-dimensional quantitative similarity-activity relationships (3D QSiAR) from SEAL similarity matrices.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID212737Binding affinity against testosterone-binding globulin (TeBG)1993Journal of medicinal chemistry, Feb-19, Volume: 36, Issue:4
Structure-activity relationships from molecular similarity matrices.
AID51052In silico binding affinity to corticosteroid binding globulin (CBG)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.
AID1241422Inhibition of 17beta-HSD3 in rat testes microsomes using [14C]-4-androstene-3,17-dione as substrate after 2 hrs2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.
AID212931Binding affinity towards human testosterone binding globulin.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID382396Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus laevis assessed as ratio of current in treated to non-treated oocyte at 0.1 uM by electrophysiology2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID659063Modulation of rat alpha1beta2gamma2L GABAA receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride currents at 10 uM by electrophysiology assay relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on γ-aminobutyric acid type A receptors.
AID266555Activity at rat GABA-Aalpha1 receptor plus beta-2-gamma-2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 0.1 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID324924Agonist activity at human TGR5 expressed in CHO cells by luciferase assay relative to lithocholic acid2008Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies.
AID266554Displacement of [35S]TBPS from GABA-A receptor in rat brain membrane2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID266556Activity at rat GABA-Aalpha1 receptor plus beta2gamma2L expressed in Xenopus laevis oocyte assessed as ratio of GABA-mediated current in presence to absence of compound at 1 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes.
AID321356Activity at rat GABAA alpha-1-beta-2-gamma-2L receptor expressed in Xenopus lavies oocytes assessed as ratio of effect on current at 1 uM drug to absence of compound by electrophysiology method2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neurosteroid analogues. 14. Alternative ring system scaffolds: GABA modulatory and anesthetic actions of cyclopenta[b]phenanthrenes and cyclopenta[b]anthracenes.
AID51056Binding affinity to the corticosteroid-binding globulin (CBG) receptor.2000Journal of medicinal chemistry, Aug-24, Volume: 43, Issue:17
GRid-INdependent descriptors (GRIND): a novel class of alignment-independent three-dimensional molecular descriptors.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID382392Anesthetic effect in Xenopus laevis assessed as loss of righting response2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Neurosteroid analogues. 12. Potent enhancement of GABA-mediated chloride currents at GABAA receptors by ent-androgens.
AID51048In silico binding affinity to human corticosteriod binding globulin1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1811Experimentally measured binding affinity data derived from PDB2005Protein science : a publication of the Protein Society, Jan, Volume: 14, Issue:1
The structures of the unique sulfotransferase retinol dehydratase with product and inhibitors provide insight into enzyme mechanism and inhibition.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2005Protein science : a publication of the Protein Society, Jan, Volume: 14, Issue:1
The structures of the unique sulfotransferase retinol dehydratase with product and inhibitors provide insight into enzyme mechanism and inhibition.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,028)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901473 (72.63)18.7374
1990's141 (6.95)18.2507
2000's181 (8.93)29.6817
2010's201 (9.91)24.3611
2020's32 (1.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 71.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index71.46 (24.57)
Research Supply Index7.73 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index129.80 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (71.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials67 (3.04%)5.53%
Reviews53 (2.41%)6.00%
Case Studies39 (1.77%)4.05%
Observational2 (0.09%)0.25%
Other2,041 (92.69%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]